Defective genes account for∼ 80% of the total of more than 7,000 diseases known to date.
Gene therapy brings the promise of a one-time treatment option that will fix the errors in …

Despite scientific discoveries in the field of gene and cell therapy, some diseases still have
no effective treatment. Advances in genetic engineering methods have enabled the …

Abstract Reports of Guillain-Barré syndrome (GBS) have emerged during the Coronavirus
disease 2019 (COVID-19) pandemic. This epidemiological and cohort study sought to …

Adeno-associated virus (AAV) has emerged as a leading platform for gene delivery for
treating various diseases due to its excellent safety profile and efficient transduction to …

Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their
stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample …

Adeno-associated viruses (AAV) have emerged as the lead vector in clinical trials and form
the basis for several approved gene therapies for human diseases, mainly owing to their …

Over the last two decades, gene therapy vectors based on wild‐type Adeno‐associated
viruses (AAV) are safe and efficacious in numerous clinical trials and are translated into …

In recent years, the biopharmaceutical industry's interest in gene therapy modalities has
increased dramatically. To warrant their quality during manufacturing and …

With a limited coding capacity of 4.7 kb, adeno-associated virus (AAV) genome has evolved
over-lapping genes to maximise the usage of its genome. An example is the recently found …

Over recent decades, therapeutic proteins have had widespread success in treating a
myriad of diseases. Glycosylation, a near universal feature of this class of drugs, is a critical …